KPV — questions, answered plainly.

KPV is the C-terminal tripeptide of α-melanocyte-stimulating hormone — Lys-Pro-Val (α-MSH 11-13). It is studied as an anti-inflammatory peptide independent of classical melanocortin receptor signalling.

Despite being derived from α-MSH, KPV's anti-inflammatory effects appear largely melanocortin-receptor-independent. Getting 2003 (J Pharmacol Exp Ther, PMID 12750433) showed the effects persist in mice deficient in melanocortin signalling, suggesting an alternative pathway likely involving IL-1β inhibition.

Dalmasso 2008 (Gastroenterology, PMID 18061177) reported that KPV is taken up by intestinal cells via the PepT1 transporter and was associated with reduced inflammatory signalling and reduced colitis severity in mouse DSS and TNBS colitis models.

PepT1 (SLC15A1) is a di- and tripeptide transporter expressed on intestinal epithelium. The Dalmasso 2008 work identified PepT1 as the route by which orally administered KPV reaches the inflamed intestinal mucosa in the colitis models studied.

No. KPV is not approved as a medicine in any jurisdiction. The published primary evidence base is in vitro and rodent; controlled human trials are limited.

Most primary research is in vitro or in rodent inflammation models. Clinical evidence in humans is limited. KPV is not approved for any therapeutic indication.